Adalvo, in collaboration with its strategic partner CNX Therapeutics, has launched Nitrofurantoin Modified Release Tablets in the Netherlands, marking the first generic entry in these markets.
Developed in-house, this milestone comes despite the formulation patent for the reference product expiring in 2007, highlighting Adalvo’s capability to bring differentiated, high-value treatments to market.
Nitrofurantoin is a trusted first-line antibiotic for urinary tract infections (UTIs). With a well-established safety profile and minimal side effects, it remains the go-to treatment for healthcare providers and patients alike.
As the global UTI market is projected to grow from $7.2 billion in 2024 to $14.28 billion by 2031 at a CAGR of 10.23% (Coherent MI), this launch positions Adalvo to address a significant and growing need.
"Our ability to be first to market with Nitrofurantoin in the Netherlands reflects our commitment to excellence and our focus on bringing differentiated, cost-effective treatments to patients," said Anil Okay, CEO of Adalvo.
“We’re proud to bring Nitrofurantoin to the Netherlands as the first generic, reinforcing our mission to provide innovative, high-quality products that meet healthcare demands,” said Ben Moore, Vice President, Corporate Development at CNX Therapeutics. “Our partnership with Adalvo continues to play a pivotal role in delivering accessible treatments to patients.”
Adalvo continues to demonstrate its commitment to expanding access to essential medicines worldwide through expertise and strategic partnerships.
Contact Our Team To Explore Commercial Opportunities
Partner with us to shape the future of healthcare.
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 19 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customised to our partners, and designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help our partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.
The company’s purpose-driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About CNX
CNX Therapeutics is a speciality pharmaceutical company committed to improving the lives of patients by providing access to essential medicines. CNX commercialises and distributes a portfolio of pharmaceuticals for neurological, psychiatric and hospital emergencies in over 60 markets worldwide, both directly and through strategic partnerships, and is an attractive partner for companies who are looking for a pan-European partner for Central Nervous System (CNS) and hospital injectable products, which is committed to the highest standards of ethics and sustainability. For more information, visit: www.cnx-therapeutics.com
Disclaimer: The decision may be subject to appeal. Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.